Nevada AB555 establishes a $35 cap on cost-sharing for a 30-day supply of prescription insulin drugs under certain health insurance policies.
Nevada AB555 amends existing law to establish a $35 cap on cost-sharing for a 30-day supply of prescription insulin drugs for insured individuals under certain health insurance policies. This applies to insurers, health maintenance organizations, and other health care providers. The bill also mandates coverage for diabetes management and treatment, including self-management training and education. It authorizes the Commissioner of Insurance to enforce these provisions and take action against non-compliant organizations. The changes apply to policies renewed or issued after October 1, 2025.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.